Trial · NCT02817347
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of patients achieving cessation of otorrhea on Day 15. | Day 15 | The proportion of patients achieving cessation of otorrhea (grade 0) on Day 15, as evidenced by otoscopy |
| Secondary | The proportion of patients with cessation of otorrhea on Day 8. | Day 8 | The proportion of patients with cessation of otorrhea on Day 8 as evidenced by otoscopy. |
| Secondary | The proportion of patients with cessation of otorrhea on Day 22. | Day 22 | The proportion of patients with cessation of otorrhea on Day 22 as evidenced by otoscopy. |
| Secondary | Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy | Day 8 | 'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale |
| Secondary | Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy | Day 15 | 'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale |
| Secondary | Proportion of patients with improved otorrhea at each visit, as evidenced by otoscopy | Day 22 | 'improved otorrhea' is defined as at least one level decrease from baseline in the otorrhea severity grading scale |
| Secondary | Microbiological eradication | Day 8, 15, 22 | Proportion of patients with microbiological eradicationat each visit |
| Other | Cmax | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | Maximum plasma concentration |
| Other | AUClast | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | The area under the plasma concentration-time curve from time zero until the last measurable concentration |
| Other | AUCinf | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | The area under the plasma concentration - time curve from time zero to infinite time |
| Other | Tmax | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | Time to reach Cmax |
| Other | t1/2 | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | Terminal elimination half-life |
| Other | CL/F | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | Apparent plasma clearance |
| Other | Vd/F | pre-dose, and at 0.25, 0.5, 1, 2, 4 and 6 hours | Apparent volume of distribution |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02817347/registered